Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1899 1
1920 1
1979 1
1989 1
1990 1
1995 2
1996 4
1997 3
1998 2
1999 6
2000 3
2001 2
2002 9
2003 16
2004 23
2005 19
2006 18
2007 17
2008 14
2009 7
2010 12
2011 10
2012 7
2013 12
2014 17
2015 13
2016 14
2017 12
2018 10
2019 10
2020 13
2021 6
2022 12
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

296 results

Results by year

Filters applied: . Clear all
Page 1
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB, Lu Q, Kusmiati T, Balanag VM, Lee SL, Ruslami R, Pokharkar Y, Djaharuddin I, Sugiri JJR, Veto RS, Sekaggya-Wiltshire C, Avihingsanon A, Sarin R, Papineni P, Nunn AJ, Crook AM; TRUNCATE-TB Trial Team. Paton NI, et al. N Engl J Med. 2023 Mar 9;388(10):873-887. doi: 10.1056/NEJMoa2212537. Epub 2023 Feb 20. N Engl J Med. 2023. PMID: 36808186 Clinical Trial.
Recent advances in the treatment of tuberculosis.
Motta I, Boeree M, Chesov D, Dheda K, Günther G, Horsburgh CR Jr, Kherabi Y, Lange C, Lienhardt C, McIlleron HM, Paton NI, Stagg HR, Thwaites G, Udwadia Z, Van Crevel R, Velásquez GE, Wilkinson RJ, Guglielmetti L; Study group on Mycobacteria (ESGMYC) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Motta I, et al. Among authors: paton ni. Clin Microbiol Infect. 2023 Jul 22:S1198-743X(23)00339-7. doi: 10.1016/j.cmi.2023.07.013. Online ahead of print. Clin Microbiol Infect. 2023. PMID: 37482332 Review.
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. INSIGHT START Study Group, et al. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20. N Engl J Med. 2015. PMID: 26192873 Free PMC article. Clinical Trial.
The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: A genotypic analysis.
Walker TM, Miotto P, Köser CU, Fowler PW, Knaggs J, Iqbal Z, Hunt M, Chindelevitch L, Farhat M, Cirillo DM, Comas I, Posey J, Omar SV, Peto TE, Suresh A, Uplekar S, Laurent S, Colman RE, Nathanson CM, Zignol M, Walker AS; CRyPTIC Consortium; Seq&Treat Consortium; Crook DW, Ismail N, Rodwell TC. Walker TM, et al. Lancet Microbe. 2022 Apr;3(4):e265-e273. doi: 10.1016/S2666-5247(21)00301-3. Lancet Microbe. 2022. PMID: 35373160 Free PMC article.
Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis.
Sonnenkalb L, Carter JJ, Spitaleri A, Iqbal Z, Hunt M, Malone KM, Utpatel C, Cirillo DM, Rodrigues C, Nilgiriwala KS, Fowler PW, Merker M, Niemann S; Comprehensive Resistance Prediction for Tuberculosis: an International Consortium. Sonnenkalb L, et al. Lancet Microbe. 2023 May;4(5):e358-e368. doi: 10.1016/S2666-5247(23)00002-2. Epub 2023 Mar 29. Lancet Microbe. 2023. PMID: 37003285 Free PMC article.
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Asienzo J, Kaimal A, Mirembe G, Lugemwa A, Ategeka G, Borok M, Mugerwa H, Siika A, Odongpiny ELA, Castelnuovo B, Kiragga A, Kambugu A; NADIA Trial Team. Paton NI, et al. Lancet HIV. 2022 Jun;9(6):e381-e393. doi: 10.1016/S2352-3018(22)00092-3. Epub 2022 Apr 20. Lancet HIV. 2022. PMID: 35460601 Free article. Clinical Trial.
Management and grading of EGFR inhibitor-induced cutaneous toxicity.
Beech J, Germetaki T, Judge M, Paton N, Collins J, Garbutt A, Braun M, Fenwick J, Saunders MP. Beech J, et al. Among authors: paton n. Future Oncol. 2018 Oct;14(24):2531-2541. doi: 10.2217/fon-2018-0187. Epub 2018 May 4. Future Oncol. 2018. PMID: 29727211 Free article. Review.
296 results